NEW YORK – Metabolomics company Metabolon announced on Tuesday that it has inked a joint development agreement with Mayo Clinic to develop diagnostic tests using metabolomic biomarkers.
Under the agreement, Metabolon will analyze patient clinical samples across different cohorts from Mayo Clinic to search for disease biomarkers and design tests for use by Mayo Clinic Laboratories. The collaboration will initially focus on metabolite biomarkers for inflammatory bowel disease and nonalcoholic fatty liver disease, Morrisville, North Carolina-based Metabolon said in a statement.
Other potential indications for collaboration include Alzheimer’s disease, pancreatic cancer, breast cancer, and inflammatory arthritis, it said.
Mayo Clinic “bring[s] significant clinical strength and robust commercialization capabilities to this vital research,” Metabolon President and CEO Rohan Hastie said in a statement. “Collaborating with Mayo Clinic has the potential to help both parties expand their cutting-edge research into the critical role of metabolomic biomarkers as valuable indicators of human health.”